GHRP-2 vs GHRP-6 vs Ipamorelin: Potency, Hunger, and Side Effect Differences

GHRP-2, GHRP-6, and Ipamorelin are all members of the growth hormone-releasing peptide (GHRP) family—they all activate the ghrelin receptor (GHS-R1a) to stimulate GH secretion from the pituitary. But their selectivity profiles differ significantly, and those differences determine which one is most appropriate for a given goal. Ipamorelin was specifically developed to address the side effect limitations of GHRP-2 and GHRP-6, and understanding that development context explains most of what you need to know.

The GHRP family: shared mechanism, different profiles

All three peptides bind to GHS-R1a, the ghrelin receptor expressed predominantly in the pituitary but also in the hypothalamus, stomach, heart, and other tissues. Activation of this receptor triggers GH release—this much is identical across the three.

Where they diverge is in their effects on other pituitary hormones and peripheral systems. GHS-R1a is not the only receptor these peptides interact with, and the degree of off-target activity determines the side effect profile.

GH release potency

In terms of raw GH-releasing potency:

| Peptide | GH Release Potency | Relative Rank | |---|---|---| | GHRP-6 | High | 1st (roughly equivalent to GHRP-2) | | GHRP-2 | High | 1st (roughly equivalent to GHRP-6) | | Ipamorelin | Moderate-High | 2nd (slightly lower per mcg vs. GHRP-2/6) |

GHRP-2 and GHRP-6 are roughly equivalent in GH-releasing potency at equivalent doses. Ipamorelin produces a somewhat lower peak GH pulse per microgram but is still meaningfully potent—particularly when combined with a GHRH analog like CJC-1295 or sermorelin.

The combination of any GHRP with a GHRH analog produces dramatically greater GH release than either alone (synergistic effect), which is why the ipamorelin/CJC-1295 stack is so popular despite ipamorelin's slightly lower standalone potency.

The critical differences: cortisol and prolactin

This is where the three peptides diverge most meaningfully:

| Side Effect | GHRP-2 | GHRP-6 | Ipamorelin | |---|---|---|---| | Cortisol elevation | Significant | Moderate | Minimal | | Prolactin elevation | Significant | Moderate | Minimal | | ACTH elevation | Significant | Moderate | Minimal | | Hunger stimulation | Moderate | Significant | Mild | | Gastric motility | Moderate | High | Low |

GHRP-2 stimulates GH release powerfully but also causes significant cortisol and prolactin release. At doses used for GH optimization, GHRP-2 can raise cortisol 1.5–2x above baseline. Elevated cortisol is catabolic—it promotes muscle breakdown, impairs sleep quality, and blunts immune function. Using a cortisol-raising peptide for muscle building or anti-aging is fundamentally counterproductive if the cortisol effect is significant.

GHRP-6 has similar issues with cortisol and prolactin but the more notorious side effect is hunger. GHRP-6 causes substantial appetite stimulation through its ghrelin-pathway effects. This is useful if you're intentionally trying to increase caloric intake (bulking phases, recovery from illness) but is a major disadvantage during cutting or caloric restriction. GHRP-6 is used by some bodybuilders specifically for appetite stimulation.

Ipamorelin was engineered to decouple GH stimulation from cortisol, prolactin, and ACTH elevation. Studies confirm that ipamorelin at therapeutic doses does not significantly raise cortisol or prolactin. Hunger stimulation is mild (much less than GHRP-6). This selective profile is why ipamorelin largely replaced GHRP-2 and GHRP-6 in clinical anti-aging practice.

Hunger: the ghrelin pathway connection

All GHRPs activate the ghrelin receptor, and ghrelin is the "hunger hormone"—one of its primary physiological roles is appetite stimulation. The degree of appetite stimulation from GHRPs correlates roughly with their ghrelin-like activity on peripheral GHS-R1a receptors in the stomach and hypothalamus:

• GHRP-6: Most significant hunger stimulation. Many users report intense, almost immediate hunger within 20–30 minutes of injection. This is dose-dependent but pronounced.
• GHRP-2: Moderate hunger stimulation—less than GHRP-6 but more than ipamorelin.
• Ipamorelin: Mild hunger stimulation. Most users don't find it significantly appetite-stimulating at standard doses.

For someone trying to lose fat while using a GHRP, ipamorelin's minimal hunger stimulation is a meaningful advantage. For someone trying to gain weight or stimulate appetite during illness or recovery, GHRP-6 might actually be desirable.

Side effects in practice

| Effect | GHRP-2 | GHRP-6 | Ipamorelin | |---|---|---|---| | Water retention | Moderate | Moderate | Mild | | Lethargy (post-injection) | Sometimes | Sometimes | Rare | | Injection site reaction | Mild | Mild | Mild | | GI discomfort | Occasional | Occasional | Rare | | Prolactin-related effects (libido, mood) | Possible at high doses | Possible | Not significant |

The cortisol and prolactin elevations from GHRP-2 aren't hypothetical—they're documented in human studies. A 1997 study by Ghigo et al. confirmed that GHRP-2 significantly elevated cortisol and prolactin in addition to GH. This research is part of why ipamorelin (developed specifically to avoid this) was considered a pharmacological improvement.

Dosing protocols

| Peptide | Standard Dose | Frequency | Notes | |---|---|---|---| | GHRP-2 | 100–300 mcg | 2–3x/day | Take fasted; food blunts GH response | | GHRP-6 | 100–300 mcg | 2–3x/day | Prepare for hunger response; best on empty stomach | | Ipamorelin | 100–300 mcg | 1–2x/day | Often combined with CJC-1295; before sleep + optional morning |

All three should be taken in a fasted state—food (particularly carbohydrates and fats) blunts GH release by triggering somatostatin release. Waiting at least 2 hours after eating before injecting maximizes the GH pulse amplitude.

Stacking with GHRH analogs

The synergistic combination of a GHRP with a GHRH analog is well-established. The three GHRPs all pair with GHRH analogs:

• Ipamorelin + CJC-1295: The gold standard combination in anti-aging medicine. Maximum GH release, minimum side effects.
• GHRP-2 + CJC-1295: More potent GH release but with cortisol elevation concerns.
• GHRP-6 + CJC-1295: Significant GH release; appropriate if appetite stimulation is desired.

For the detailed GHRH analog comparison (sermorelin vs CJC-1295), see the CJC-1295 vs Sermorelin guide.

Who should use each peptide

Choose Ipamorelin when:

• You want GH optimization without cortisol or prolactin elevation
• You're cutting or maintaining body weight (minimal hunger increase)
• Long-term anti-aging use is the goal
• You're combining with a GHRH analog (CJC-1295 or sermorelin)
• This is your first GHRP

Choose GHRP-2 when:

• Maximum raw GH pulse amplitude is the primary goal
• Short-term performance cycles where cortisol management is less of a concern
• You're combining with an aromatase inhibitor or cortisol management protocol
• Budget is extremely tight (GHRP-2 is often cheapest per mcg of GH-releasing capacity)

Choose GHRP-6 when:

• Appetite stimulation is a desired effect (recovery from illness, intentional bulking)
• You need the hunger-stimulating and gastric motility-improving effects
• GHRP-2 seems too harsh on cortisol but you still want stronger GH release than ipamorelin alone

The development timeline context

Understanding why ipamorelin exists helps contextualize the comparison. GHRP-6 was discovered first (1980s) and was an important research tool and early clinical candidate. GHRP-2 was developed as a more potent analog. Both had the problem of off-target hormone effects that limited their clinical utility. Ipamorelin (developed in the 1990s by Novo Nordisk) was specifically engineered to retain GH selectivity while eliminating cortisol, prolactin, and ACTH stimulation—it was a pharmacological refinement, not just a different molecule.

For a deep dive on ipamorelin specifically, see the ipamorelin complete guide. For GHRP-2's individual profile, the GHRP-2 guide covers it in more depth.

The bottom line

GHRP-2 and GHRP-6 release more GH per dose than ipamorelin but at the cost of significant cortisol, prolactin, and appetite side effects that undermine their usefulness for most anti-aging and body composition goals. Ipamorelin's superior selectivity makes it the preferred GHRP for the vast majority of use cases—particularly in combination with CJC-1295. GHRP-6 retains a niche in appetite stimulation applications. GHRP-2 is relevant primarily in research contexts or short-term performance protocols where maximum GH amplitude outweighs cortisol concerns.

---

Frequently Asked Questions

Q: Is ipamorelin noticeably weaker than GHRP-2 in practice? On a per-microgram basis, ipamorelin produces somewhat lower peak GH pulses than GHRP-2. However, when ipamorelin is combined with a GHRH analog (CJC-1295 or sermorelin), the combined GH release equals or exceeds what GHRP-2 produces alone. Since the combination also avoids cortisol elevation, the net effect on body composition and recovery is superior with ipamorelin + GHRH analog compared to GHRP-2 alone.

Q: How significant is the cortisol increase from GHRP-2? Published studies show GHRP-2 raises cortisol approximately 1.5–2x above baseline at standard doses (100–300 mcg). For context, a hard workout also raises cortisol significantly. Whether this is clinically meaningful depends on your baseline cortisol status and how frequently you're dosing. Users with already-elevated cortisol (high-stress jobs, sleep-deprived) are more likely to experience negative effects from GHRP-2's cortisol stimulation.

Q: Can I switch from GHRP-6 to ipamorelin mid-cycle? Yes. No washout period is required. Both work through GHS-R1a, so switching is simply substituting one peptide for another at the receptor level. Your GH response will change (less hunger, lower cortisol, slightly different peak amplitude), but there's no pharmacological issue with switching.

Q: Why do GHRPs need to be taken fasted? Elevated insulin (from eating) stimulates somatostatin release, which directly inhibits GH secretion. Taking a GHRP in a fed state blunts the GH pulse substantially—some studies suggest up to 50% reduction in GH response with a mixed meal consumed beforehand. Fasting for at least 2 hours before injection, or taking it before bed after a few hours without food, maximizes the GH response.

Q: Is there a tolerance concern with GHRPs with long-term use? Some evidence suggests GH receptor desensitization can occur with continuous high-frequency GHRP use. This is why protocols typically use daily or twice-daily dosing rather than more frequent injections, and some practitioners cycle GHRPs (5 days on, 2 days off, or monthly breaks). The evidence for tolerance is more anecdotal than rigorously documented, but cycling is a reasonable precaution for long-term use.

---

Track your GHRP protocol and GH optimization progress with Optimize.